StockData
CRISPR Therapeutics AG logo

CRISPR Therapeutics AG (CRSP) stock

CRSPNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/30
$40.15−0.22 (-0.54%)

Close on Nov 17, 2026Market cap $3.88BP/E –Yield –

CRISPR Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

CRISPR Therapeutics's price to book ratio was 2.5× on Nov 11, 2026, against 2.6× a year earlier. Over the last 5 years it ranged from 1.5× to 3.6×, with a median of 2.3×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20262.5×−0.0
2025Dec 31, 20252.6×+0.8
2024Dec 31, 20241.7×−1.1
2023Dec 29, 20232.9×+1.2
2022Dec 30, 20221.6×−0.7
2021Dec 31, 20212.3×−5.7
2020Dec 31, 20208.0×+2.4
2019Dec 31, 20195.7×+2.1
2018Dec 31, 20183.5×−1.8
2017Dec 29, 20175.3×–

More CRISPR Therapeutics figures

See a number that looks wrong?